<DOC>
	<DOCNO>NCT00152464</DOCNO>
	<brief_summary>The Early Prevention Asthma Atopic Children ( EPAAC™ ) . 24 month study evaluate efficacy safety levocetirizine ( LCTZ ) prevent onset asthma 12 24 month old child .</brief_summary>
	<brief_title>Prevention Asthma With Levocetirizine 18 Month Treatment Infants ( 12 - 24 Months ) Suffering From Eczema ( Atopic Dermatitis ) Sensitized Grass Pollen and/or House Dust Mite ( HDM )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Inclusion criterion must verify screen visit ( V1 ) : Children either sex age 12 24 month . Subjects suffer symptom Atopic Dermatitis ( AD ) last cumulatively least 2 month since birth . Modified SCORAD Index ≥ 10 Subjects whose biological mother father , one sibling welldocumented history atopy ( AD , allergic rhinitis asthma ) . Inclusion criterion must verify randomization ( V2 ) : Results RAST test GP HDM available IgE level GP ≥ 0.35 kUA/l / IgE level HDM ≥ 0.35 kUA/l . Safety laboratory result within normal range central laboratory consider clinically significant study disease relate Investigator . Exclusion criterion verify screen visit ( V1 ) : Are exclude participation study , child Have height weight 5th percentile . Have experience least one episode wheeze age 6 month . Have suffer age 6 month , least one nocturnal cough episode consist 3 ( ) consecutive night result sleep disturbance clinical set asthma likely condition exclude . Have chronic pulmonary disease type , , limit , cystic fibrosis , craniofacial abnormality , e.g. , cleft palate . Have personal history sleep apnea sibling history sleep apnea . Are treated immunomodulator medication , e.g. , cyclosporin , cyclophosphamide FK 506 ( Tacrolimus ) . Have receive receive allergen specific immunotherapy . Suffer concomitant dermatological disease/condition atopic dermatitis , might interfere evaluation clinical response atopic dermatitis . Have insufficient washout period follow medication : Intranasal systemic antihistamine : 3 day , Intranasal systemic decongestant : 3 day , Loratadine , Desloratadine : 10 day , Chromones : 2 week , Oral corticosteroid : 1 month , Chronic use ( i.e . cumulatively 2 week within last 3 month ) inhaled/intranasal corticosteroid : 1 month , Ketotifen : 1 month , Astemizole : 6 week Have treat antihistamine , include ketotifen , daily intake 2 consecutive month last 6 month screen . Subject Exclusion criterion verify randomization visit ( V2 ) : • Intake prohibit medication list selection period .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>EPAAC , atopic Children , asthma , XYZAL , levocetirizine</keyword>
</DOC>